VALUATION HIGHLIGHTS

1. Medical Devices constitute 49% of the Trefis price estimate for Abbott Labs's stock.
2. Diagnostics constitute 23% of the Trefis price estimate for Abbott Labs's stock.
3. Nutritionals constitute 17% of the Trefis price estimate for Abbott Labs's stock.

WHAT HAS CHANGED?

Latest Earnings: Q4 and Full Year 2025

Abbott reported Q4 2025 revenue of $11.46 billion, a 4.4% increase year-over-year, which missed analyst estimates of $11.8 billion. Adjusted EPS for the quarter was $1.50, representing 12% growth and meeting consensus expectations. For the full year 2025, total sales reached $44.3 billion, up 5.7% on a reported basis. Growth was primarily driven by the Medical Devices segment, which saw 12.3% reported growth in Q4, led by the FreeStyle Libre system and electrophysiology. However, the Nutrition segment struggled, with Q4 sales declining 8.9% due to lower volumes and strategic price actions. The Diagnostics segment also faced headwinds, declining 2.5% as COVID-19 testing revenue continued to normalize.

Note: Abbott's FY'25 ended on Dec. 31, 2025.

Strategic Entry into Cancer Diagnostics via Exact Sciences

In late 2025, Abbott announced a definitive agreement to acquire Exact Sciences, a leader in cancer screening and diagnostics. This strategic move is designed to position Abbott as a dominant player in the rapidly expanding oncology diagnostics market, complementing its existing Core Lab and Molecular Diagnostics leadership. The acquisition is expected to close in the second quarter of 2026 and adds a high-growth pipeline to Abbott's portfolio, specifically in non-invasive colorectal cancer screening. This pivot aligns with management's goal of diversifying beyond COVID-19 testing revenue and capturing long-term value in specialized diagnostic sectors.

POTENTIAL UPSIDE & DOWNSIDE TO TREFIS PRICE

Below are key drivers of Abbott's value that present opportunities for upside or downside to the current Trefis price estimate:

Medical Devices

• Diabetes Care Expansion: The FreeStyle Libre platform remains Abbott's primary growth engine, with sales exceeding $7.5 billion in 2025. Management has set a target of $10 billion in annual sales by 2028. Continued adoption of the Libre 3 and the dual glucose-ketone sensor presents significant upside if market penetration in the Type 2 non-insulin-using population accelerates faster than Trefis' current adoption curve.


• Electrophysiology Innovation: The recent FDA approval of the Volt PFA System and the CE Mark for the TactiFlex Duo catheter allow Abbott to compete in the high-growth Pulsed Field Ablation market. If these launches capture significant market share from traditional radiofrequency ablation, there is potential for margin expansion and revenue growth exceeding current mid-single-digit estimates for the cardiovascular division.

For additional details, select a division from the interactive Trefis split for Abbott at the top of the page.

BUSINESS SUMMARY

Abbott Laboratories operates a diversified healthcare model across four primary segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. The company leverages its massive global footprint and leadership in chronic disease management—particularly in diabetes and cardiovascular health—to generate stable cash flows. While its Diagnostics business is transitioning through a post-pandemic recalibration, its Medical Devices division has emerged as the high-growth core, supported by a robust R&D pipeline and strategic acquisitions.

SOURCES OF VALUE

Abbott's diversified portfolio provides a unique hedge against sector-specific volatility, but its competitive edge is most concentrated in its high-tech medical segments.

Global Leadership in CGM Technology

Abbott's FreeStyle Libre is the world's most widely used continuous glucose monitoring system. This dominance is protected by a massive installed base, a lower price point than primary competitors, and an expanding ecosystem of digital health tools that create high switching costs for patients and providers.

Emerging Market Pharmaceutical Moat

The Established Pharmaceuticals Division (EPD) focuses on branded generics in high-growth emerging markets like India and Latin America. By localizing manufacturing and tailoring product portfolios to regional therapeutic needs, Abbott maintains higher margins and brand loyalty than standard generic manufacturers, creating a durable "staple-like" revenue stream.

KEY TRENDS

Shift Toward Minimally Invasive Procedures

There is a significant industry shift toward minimally invasive cardiovascular and structural heart interventions. Abbott is capitalizing on this through its portfolio of transcatheter valves (Navitor, TriClip) and PFA technologies, which reduce hospital stays and improve patient outcomes compared to traditional open-heart surgeries.

Post-Pandemic Diagnostic Realignment

As COVID-19 testing becomes a negligible portion of the business, Abbott is refocusing its Diagnostics strategy on high-volume Core Lab automation and specialized molecular testing. The acquisition of Exact Sciences signifies a shift toward high-acuity diagnostic areas like oncology to offset the loss of pandemic-related revenue.

Nutrition Volume Recovery Strategy

Following a year of price-driven volume constraints, Abbott is pivoting its Nutrition strategy to focus on volume growth. This includes the launch of specialized products like Protality, designed for patients using GLP-1 weight-loss drugs, targeting a new and rapidly growing demographic of health-conscious consumers.